首页> 外文期刊>Physiological Research >Deconjugated Urinary Metanephrine, Normetanephrine and 3-Methoxytyramine in Laboratory Diagnosis of Pheochromocytoma and Paraganglioma
【24h】

Deconjugated Urinary Metanephrine, Normetanephrine and 3-Methoxytyramine in Laboratory Diagnosis of Pheochromocytoma and Paraganglioma

机译:解离的尿中肾上腺素,去甲肾上腺素和3-甲氧基酪胺在嗜铬细胞瘤和副神经节瘤的实验室诊断中

获取原文
获取原文并翻译 | 示例
           

摘要

This work discusses the clinical performance of deconjugated metanephrine (MN), normetanephrine (NMN) and 3-methoxytyramine (3MT) determined in the basal first morning urine using a chromatographic method with electrochemical detection for the clinical diagnosis of pheochromocytoma (PHEO) and paraganglioma (PGL). Urine samples were collected from 44 patients (36 with PHEO, 8 with PGL) aged 54+/-17 (20-78) years (22 females, 22 males). A sampling of biological materials was performed preoperatively and about one week, six months and one year after adrenal gland surgery. The control group consisted of 34 PHEO/PGL patients more than 4 months after adrenal gland surgery. All subjects in the control group were without a diagnosis of PHEO or PGL. Clinical sensitivity was 55 % for MN, 64 % for NMN, 80 % for combination of both MN and NMN, and only 23 % for 3TM. Clinical specificity calculated from the control group was 93 % for MN, 95 % for NMN, 95 % for the combination MN and NMN, and 97 % for 3TM. Cut-off values for deconjugated metanephrines in the basal urine were 310 (MN), 690 (NMN) and 250 mu g/l (3MT). Chromatographic determination of deconjugated urinary metanephrines, which is simple without the necessity of special laboratory material, can serve for the screening of PHEO or PGL patients. Urine NMN and 3MT exerts an association to malignity, and all markers are associated with tumor mass. However, the principal laboratory diagnosis of PHEO or PGL must be based on plasma-free metanephrines and plasma chromogranin A with better performance in the laboratory diagnosis of PHEO or PGL.
机译:这项工作讨论了使用电化学检测色谱方法在基底第一清晨尿液中测定的共轭去甲肾上腺素(MN),去甲肾上腺素(NMN)和3-甲氧基酪胺(3MT)的临床表现,用于临床诊断嗜铬细胞瘤(PHEO)和副神经节瘤( PGL)。从44 +/- 17(20-78)岁的44名患者(36名PHEO,8名PGL)患者(22名女性,22名男性)中收集尿液样本。术前以及肾上腺手术后大约一周,六个月和一年对生物材料进行了采样。对照组由肾上腺手术后4个月以上的34名PHEO / PGL患者组成。对照组中的所有受试者均未诊断为PHEO或PGL。 MN的临床敏感性为55%,NMN的临床敏感性为64%,MN和NMN的组合的临床敏感性为80%,而3TM的临床敏感性仅为23%。从对照组计算出的临床特异性对于MN为93%,对于NMN为95%,对于MN和NMN组合为95%,对于3TM为97%。基尿中去结合的去甲肾上腺素的临界值为310(MN),690(NMN)和250μg / l(3MT)。色谱法测定解离的尿中新肾上腺素很简单,无需特殊的实验室材料,可用于筛查PHEO或PGL患者。尿液NMN和3MT与恶性肿瘤有关,所有标志物均与肿瘤肿块有关。但是,对PHEO或PGL的主要实验室诊断必须基于无血浆的肾上腺素和血浆嗜铬粒蛋白A,它们在PHEO或PGL的实验室诊断中表现更好。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号